New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2013
07:41 EDTBIIBBiogen drops 7% after ALS drug misses endpoint in trial
Shares of Biogen Idec (BIIB) are down 7% in pre-market trading after the company said its Phase 3 trial investigating dexpramipexole in people with amyotrophic lateral sclerosis, or ALS, did not meet its primary endpoint. Biogen said it will discontinue development of dexpramipexole in ALS due to the trial results. Note earlier this morning, Piper Jaffray cut its rating on shares of Biogen to Neutral from Overweight. The stock is currently trading lower 7%, or $10.01, to $139.99 in pre-market trading.
News For BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
07:39 EDTBIIBBiogen reinstated with a Neutral at BofA/Merrill
Subscribe for More Information
September 29, 2014
07:26 EDTBIIBInforma Business Information to hold a conference
Subscribe for More Information
September 22, 2014
07:21 EDTBIIBEBD Group to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use